For years, healthcare professionals have turned to metformin as a potential aid for individuals with type 1 diabetes, aiming to enhance insulin resistance based on limited prior evidence. Recent findings from a controlled clinical trial, however, reveal that while metformin does not improve insulin resistance, it significantly lowers the amount of insulin required to maintain healthy blood sugar levels.
Published in Nature Communications, this study uncovers a promising advantage that could alleviate the daily burdens faced by those dependent on insulin therapy.
The Challenge of Type 1 Diabetes Management
Type 1 diabetes is an autoimmune disorder affecting over 130,000 Australians, where the immune system attacks insulin-producing cells in the pancreas. Consequently, patients must rely on insulin for life to regulate their blood sugar levels.
Managing this condition can be overwhelming, as individuals with type 1 diabetes make approximately 180 additional decisions each day related to blood sugar monitoring and adjustments.
Many patients experience insulin resistance over time, which reduces their body's responsiveness to insulin, often leading to increased doses to maintain stable blood sugar levels.
"Insulin resistance is an escalating issue in type 1 diabetes. It complicates blood sugar regulation and poses an overlooked risk for cardiovascular diseases, a leading cause of health complications in these patients," notes Dr. Jennifer Snaith, an endocrinologist and co-lead of the study.
Exploring Metformin's Impact
To investigate metformin's potential benefits, researchers conducted the first randomized controlled trial targeting adults with type 1 diabetes, known as the Insulin Resistance in Type 1 Diabetes Managed with Metformin (INTIMET) study. This trial aimed to determine if metformin could effectively reduce insulin resistance in this demographic.
While metformin is widely used for type 2 diabetes and has been prescribed off-label to around 13,000 Australians with type 1 diabetes, its specific effects in this group have remained unclear.
"We enrolled 40 adults with long-term type 1 diabetes to receive either metformin or a placebo for six months. We assessed insulin resistance through advanced techniques, including a clamp study," explains Professor Greenfield.
Surprising Findings on Insulin Usage
Contrary to expectations, the results showed no improvement in insulin resistance or significant changes in blood sugar levels among participants taking metformin.
However, a notable outcome emerged: those on metformin required approximately 12% less insulin than their placebo counterparts to maintain stable blood sugar levels.
"Although we didn't observe changes in insulin resistance, the reduction in insulin usage is significant. Insulin, while lifesaving, can impose considerable mental and physical burdens. Thus, minimizing insulin intake is crucial for many living with type 1 diabetes. This study suggests that a low-cost, accessible medication may fulfill this need, which is truly exciting," Dr. Snaith states.
Investigating the Gut Microbiome's Role
Researchers are now delving into why metformin lowers insulin requirements without affecting insulin resistance.
Professor Greenfield elaborates: "Metformin has been in use for nearly a century, yet its mechanism remains elusive. We anticipated that the reduction in insulin dosage would correlate with increased insulin sensitivity, but our findings indicate otherwise. Our next step is to uncover how metformin achieves this effect."
One intriguing hypothesis involves the gut microbiome, as researchers suspect that metformin may alter gut bacteria in ways that influence glucose processing.
"Emerging evidence suggests metformin's actions may extend to the gut. We are now investigating how it modifies gut flora in individuals with type 1 diabetes, an area previously unexplored. We hope this research will clarify metformin's mechanism and broaden its application in managing type 1 diabetes," Dr. Snaith adds.
Research Support and Team
This groundbreaking research is backed by the Diabetes Australia Research Program, St Vincent's Clinic Research Foundation, and several other esteemed organizations.
Dr. Jennifer Snaith, an endocrinologist at St Vincent's Hospital Sydney, leads the Australian Collaborative Towards Adjunctive Therapies in Type 1 Diabetes (ACT-T1D), while Professor Jerry Greenfield heads the Department of Diabetes and Endocrinology at St Vincent's Hospital and serves as Chair of ACT-T1D.
